荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 09-04 16:08:03

80.000

-1.200

-1.48%

最高83.400	最低79.300	成交量285.60万
今开81.700	昨收81.200	日振幅5.05%
总市值450.89亿	流通市值166.86亿	总股本5.64亿
成交额2.31亿	换手率1.37%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":80,"timestamp":1788509283009,"preClose":81.2,"halted":0,"volume":2856020,"delay":0,"changeRate":-0.014778325123152743,"floatShares":208581239,"shares":563608243,"eps":1.507695401622957,"marketStatus":"休市中","change":-1.2,"latestTime":"09-04 16:08:03","open":81.7,"high":83.4,"low":79.3,"amount":231189458,"amplitude":0.050493,"askPrice":80.2,"askSize":3500,"bidPrice":80,"bidSize":15000,"shortable":3,"etf":0,"ttmEps":12.139208357411112,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":81.2,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":1.2095933635042655,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":124.24,"timestamp":1788505200000,"preClose":127.55,"halted":0,"volume":5114900,"delay":0,"premium":"-44.91"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"1162679196","title":"荣昌生物更新2026年8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1162679196","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162679196?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:02","pubTimestamp":1788512522,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年9月4日披露2026年8月股份变动月报表，报告期截至2026年8月31日。两类股份的法定（注册）股本均与上月保持一致。报告期内，H股已发行股份维持在208,581,239股，无新增发行或库存股份变动。期间，公司的购回活动主要发生在2026年8月3日，当日公司对A股进行了回购28,040股，这些股份用于未来的股权激励计划或在未能于既定期限内使用情形下予以注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800103","title":"东海证券：给予荣昌生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800103?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:32","pubTimestamp":1788481936,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏近期对荣昌生物进行研究并发布了研究报告《公司简评报告：业绩亮眼，研发国际化加速推进》，给予荣昌生物买入评级。　　荣昌生物　　投资要点　　公司业绩表现靓丽。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为161.61。本文数据来源于东海证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400007902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664536817","title":"荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664536817","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664536817?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:04","pubTimestamp":1788357855,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，荣昌生物报收于123.57元，较前一交易日上涨3.28%，最新总市值为697.52亿元。近日，荣昌生物发布《关于2026年第一次以集中竞价交易方式回购公司股份的进展公告》。公告显示，公司于2026年7月19日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2026年7月19日至2027年7月18日，拟回购金额为2,500万元至5,000万元，回购价格不超过149元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2148510915.USD","LU1969619763.USD","LU2488822045.USD","BK0239","688331","LU1064130708.USD","09995","LU1064131003.USD","BK1583","LU2328871848.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184125837","title":"荣昌生物（09995）披露2026年首次A股回购进展：已耗资447.67万元回购4.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1184125837","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184125837?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:01","pubTimestamp":1788350494,"startTime":"0","endTime":"0","summary":"荣昌生物9月3日发布公告，通报其2026年第一次以集中竞价交易方式回购A股股份的最新进展。截至2026年8月31日，公司已通过上海证券交易所交易系统累计回购41,040股，约占公司5.64亿股总股本的0.0073%。回购成交价格区间为每股108.30元至109.99元，已支付资金总额4,476,708元，折合约447.67万元。公司表示，本次回购行为符合《上市公司股份回购规则》及上海证券交易所相关自律监管指引的规定，将在回购期限内根据市场情况继续实施，并按规定及时披露进展信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819216","title":"荣昌生物(09995)：截至8月末累计回购4.1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819216","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819216?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:01","pubTimestamp":1788350479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，截至2026年8月31日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份4.1万股，占公司总股本的比例为0.0073%，回购成交的最高价为109.99元/股，最低价为108.30元/股，支付的资金总额为人民币447.67万元(不含交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03188","83188","09995","03130","82846","BK1583","688331","BK1574","02827","07233","LU1969619763.USD","LU1064130708.USD","LU2148510915.USD","02846","BK1161","LU1064131003.USD","LU2328871848.SGD","83130","BK1147","LU2488822045.USD","BK0239","399300","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819359","title":"执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819359","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819359?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:38","pubTimestamp":1788349091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月27日，执行董事王玉晓减持荣昌生物(09995)1.35万股，每股作价81.5352港元，总金额约为110.07万港元。减持后最新持股数目为2227.86万股，最新持股比例为10.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","EWH","LU1969619763.USD","BK1574","688331","LU1064130708.USD","09995","LU1064131003.USD","LU2148510915.USD","BK0239","BK1583","LU2488822045.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781507","title":"荣昌生物(09995.HK)购买3亿元理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664781507?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:11","pubTimestamp":1788347501,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1969619763.USD","BK1583","09995","LU2328871848.SGD","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120766540","title":"荣昌生物：王玉晓减持，好仓比例降至10.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120766540","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120766540?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:42","pubTimestamp":1788342122,"startTime":"0","endTime":"0","summary":"王玉晓于2026年8月27日以每股均价81.5352港元卖出荣昌生物（09995）1.35万股，涉资约110.07万港元。王玉晓此次减持前持有荣昌生物好仓2229.21万股，占比10.69%；减持后持股量为2227.86万股，好仓比例降至10.68%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664557708","title":"执行董事王玉晓减持荣昌生物(09995)6500股 每股作价82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664557708","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664557708?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:35","pubTimestamp":1788262545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月26日，执行董事王玉晓减持荣昌生物(09995)6500股，每股作价82港元，总金额为53.3万港元。减持后最新持股数目为2229.21万股，最新持股比例为10.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","688331","BK0239","LU2488822045.USD","BK1161","LU2148510915.USD","LU1064130708.USD","LU2328871848.SGD","EWH","BK1574","LU1064131003.USD","BK1583","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663250100","title":"中金：维持荣昌生物(09995)跑赢行业评级 目标价112.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663250100","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663250100?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:39","pubTimestamp":1788140361,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持荣昌生物跑赢行业评级，维持2026/2027年归母净利润预测40.25/5.83亿元不变。基于DCF估值，维持目标价112.92港元不变，相较当前股价有34.8%上行空间。公司收到与艾伯维关于RC148合作授权协议的6.5亿美元首付款拉动技术授权收入大幅增加，1H26业绩符合该行预期。此外泰它西普已被纳入《国家基本药物目录》内“免疫系统用药”，该行认为有望进一步提升在基层市场的用药可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663461010","title":"每周股票复盘：荣昌生物（688331）Q2收入同比增808.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663461010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663461010?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:33","pubTimestamp":1788031989,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，荣昌生物报收于119.73元，较上周的125.5元下跌4.6%。本周，荣昌生物8月26日盘中最高价报125.66元。股本股东变化截至2026年6月30日，公司股东户数为2.42万户，较3月31日增加4489.0户，增幅22.76%。公司公告汇总荣昌生物2026年半年度报告摘要显示，报告期末公司总资产为9,847,249,925.82元，较上年度末增长35.86%；归属于上市公司股东的净资产为8,314,075,106.28元，较上年度末增长130.38%。荣昌生物披露2026年上半年募集资金存放与实际使用情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995","LU1064130708.USD","BK1161","LU1969619763.USD","BK0239","LU2328871848.SGD","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729977","title":"【券商聚焦】国投证券：创新药有望开启新一轮高景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729977","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729977?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:29","pubTimestamp":1787794154,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究指，医药景气新周期背景下，国内创新药产业链加速崛起。近年国家多举措全链条支持创新药发展，叠加国内得天独厚的人才储备和研发效率等多维优势，国内创新药持续加速崛起且逐步具备全球竞争力。与此同时，海外MNC陆续面临专利悬崖困境，对外采购和扩充创新管线需求与日俱增，国内创新药企顺势而为，以海外授权BD等形式实现创新出海，创新药有望开启新一轮高景气周期。风险提示：产品研发及审批速度低于预期；产品降价超预期风险；海外BD授权不及预期风险；计算及假设不及预期风险。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","KCE","LU0307460666.USD","LU0634319403.HKD","01093","LU0516422952.EUR","06185","LU2242644610.SGD","LU1770034418.SGD","LU0455707207.USD","LU0348767384.USD","LU0417516738.SGD","LU0314109678.HKD","02269","LU0326950275.SGD","IE00BPRC5H50.USD","LU0140636845.USD","KURE","LU1807302812.USD","LU1226287875.USD","LU0051755006.USD","LU0359201612.USD","159992","LNGR","01801","09926","06978","LU0880133367.SGD","SG9999004220.SGD","LU0516423091.SGD","06160","LU1794554557.SGD","IE0008369823.USD","161027","LU0039217434.USD","BK1589","IBBQ","LU0463099449.HKD","LU0348825331.USD","LU1813983027.USD","01877","SG9999002562.SGD","LU0348783233.USD","MEDX","01177","09995","LU1969619763.USD","02616","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791545","title":"花旗：升荣昌生物(09995)目标价至127.7港元 续予“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662791545?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:12","pubTimestamp":1787735524,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，荣昌生物(09995)上半年收入同比增长433%，亏转盈赚46.6亿元人民币。管理层表示，剔除BD收入后上半年净亏损约2,600万元人民币，预期剔除BD收入后，2026财年可实现收支平衡。目标价由105港元升至127.7港元，续予“买入/高风险”评级。该行表示，泰它西普及维迪西妥单抗展现强劲的按季销售增长，又相信RC148交易可重塑公司的增长轨道。该行上调公司2026至28年的收入预测3%、22%及18%，并将每股盈测调升至8.5元、2.2元及2.7元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","EWH","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662962387","title":"中银国际：维持荣昌生物(09995.HK)“买入”评级 目标价下调至114港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662962387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662962387?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:29","pubTimestamp":1787732947,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1969619763.USD","BK1574","BK1161","09995","BK1583","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796640","title":"里昂：升荣昌生物(09995)目标价至144.8港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796640","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796640?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:16","pubTimestamp":1787732166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，荣昌生物(09995)2026年第二季销售同比增长808.6%，净利43.34亿元人民币，两者均超出市场预期，受惠于RC18强劲销售势头及RC148对外授权费用贡献。管理层维持2026年全年营运盈亏平衡指引。公司RC148、RC18及RC48的海外进展按计划进行。考虑到业绩表现，该行修订预测，将荣昌生物2026财年销售预测上调52.6%，2027和2028财年预测下调23.8%/12.1%。2026财年净利预测上调136.8%，2027和2028财年预测下调65.1%/25.2%;并将目标价由136.9港元上调至144.8港元。维持“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","EWH","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166012742","title":"异动解读｜荣昌生物盘中上涨5.04%，中期业绩扭亏叠加生物科技板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1166012742","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166012742?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:38","pubTimestamp":1787708332,"startTime":"0","endTime":"0","summary":"8月26日，荣昌生物盘中上涨5.04%，报84.0港元，成交额8473.6万港元。消息面上，公司8月24日披露半年报，上半年实现营收58.53亿元，同比增长433.11%；归母净利润46.62亿元，同比扭亏为盈。业绩大幅增长主要源于与艾伯维就RC148签署独家授权许可协议所确认的技术授权收入，仅首付款一项即贡献巨额利润。此外，核心产品泰它西普、维迪西妥单抗国内销售收入亦持续增长。当日生物科技板块整体走强，信达生物涨11.19%、云顶新耀涨9.07%、康方生物涨6.86%，板块共振助推。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物盘中上涨，扭亏为盈引爆行情","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750819","title":"荣昌生物（688331）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750819","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750819?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:16","pubTimestamp":1787696181,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期荣昌生物发布2026年中报。截至本报告期末，公司营业总收入58.53亿元，同比上升433.11%，归母净利润46.62亿元，同比上升1137.06%。按单季度数据看，第二季度营业总收入51.97亿元，同比上升808.6%，第二季度归母净利润43.34亿元，同比上升2317.88%。本报告期荣昌生物盈利能力上升，毛利率同比增幅13.86%，净利率同比增幅294.53%。本文数据来源于荣昌生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773013","title":"荣昌生物上半年赚逾46亿元背后：新药海外授权交易首付款贡献巨额利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773013","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773013?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:40","pubTimestamp":1787665201,"startTime":"0","endTime":"0","summary":"凭借一笔价值数十亿美元的海外授权交易，荣昌生物（SH688331）在2026年上半年实现了业绩逆转。8月24日晚间，荣昌生物披露的半年报显示，今年上半年，公司归母净利润逾46亿元，而去年同期亏损4.50亿元。这一同比“扭亏为盈”的亮眼成绩，主要得益于公司与国际制药巨头艾伯维就新药RC148达成的独家授权协议，仅首付款一项便为公司带来了巨额的技术授权收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253853325244.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253853325244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","09995","LU1064130708.USD","BK1161","LU1969619763.USD","BK0239","LU2328871848.SGD","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782245","title":"8月25日荣昌生物涨5.11%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662782245?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:37","pubTimestamp":1787647026,"startTime":"0","endTime":"0","summary":"证券之星消息，8月25日荣昌生物涨5.11%，收盘报122.37元，换手率3.24%，成交量11.52万手，成交额13.88亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共121家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK1583","LU1969619763.USD","BK0239","LU2328871848.SGD","LU2488822045.USD","688331","160916","BK1161","LU1064131003.USD","09995","BK1574","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107787887","title":"异动解读｜荣昌生物盘中上涨5.12%，中期业绩扭亏为盈提振早盘买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1107787887","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107787887?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:55","pubTimestamp":1787622956,"startTime":"0","endTime":"0","summary":"8月25日，荣昌生物盘中上涨5.12%，报78.0港元，成交额1.06亿港元。消息面上，公司8月24日晚间披露半年报，上半年实现营业收入58.53亿元，同比增长433.11%；归母净利润46.62亿元，同比扭亏为盈；经营现金流净额42.14亿元，同比增长1816.2%。生物科技板块整体偏暖，云顶新耀涨4.12%、百济神州涨1.54%，板块共振助推。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物盘中上扬，扭亏为盈提振买盘","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0453},{"period":"1month","weight":-0.0309},{"period":"3month","weight":0.1348},{"period":"6month","weight":-0.0621},{"period":"1year","weight":-0.1155},{"period":"ytd","weight":0.1111}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.049233},{"month":6,"riseRate":0.666667,"avgChangeRate":0.089626},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.010221},{"month":8,"riseRate":0.333333,"avgChangeRate":0.055035},{"month":9,"riseRate":0.5,"avgChangeRate":0.081239},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}